cediranib   Click here for help

GtoPdb Ligand ID: 5664

Synonyms: AZD 2171 | AZD2171 | ZD 2171
Compound class: Synthetic organic
Comment: Cediranib is a highly potent VEGFR2 (KDR) inhibitor [2]. This compound was in the AstraZeneca/NCATS repurposing list from 2012.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 72.5
Molecular weight 450.21
XLogP 4.12
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COc1cc2c(ncnc2cc1OCCCN1CCCC1)Oc1ccc2c(c1F)cc([nH]2)C
Isomeric SMILES COc1cc2c(ncnc2cc1OCCCN1CCCC1)Oc1ccc2c(c1F)cc([nH]2)C
InChI InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3
No information available.
Summary of Clinical Use Click here for help
Cediranib has been evaluated in clinical trial as a treatment for several types of malignancies, including non-small cell lung cancer, kidney cancer, colorectal cancer and central nervous system cancer (in children). Several trials have been terminated or have not progressed further. The most advanced trials that are active (as of Oct 2018) are Phase 3 studies in ovarian cancer patients (NCT03278717; as a potential maintenance therapy) and patients with BRCA rearranged ovarian, fallopian tube, or primary peritoneal cancers (NCT02446600). Click here to view the full list of cediranib trials that are registered with ClinicalTrials.gov.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Inhibition of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis reduces the vascularisation which underpins and supports tumour development and growth in some cancers.